Abstract:β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a key enzyme to cleave the amyloid precursor protein to develop Alzheimer's disease (AD). Reducing BACE1 expression in central neuron through RNA interference technology shows great promise to overcome AD. However, to obtain an efficient and neurons-specific delivery of siRNA against BACE1 through systemic administration remains challenging. Here, we design and prepare siRNA nano-carriers based on PEGylated poly(2-(N,N-dimethylamino) ethyl methacrylate) (PEG-PDMAEMA) modified with both the CGN peptide for blood-brain barrier (BBB) penetration and the Tet1 peptide for neuron-specific binding. The nanocomplexes CT/siRNA, composed of CGN-PEG-PDMAEMA and Tet1-PEG-PDMAEMA at a weight ratio of 1:1, display a good stability in the blood and do not lead to hemolysis at N/P = 10. The internalization of nanocomplexes in neuron cells relies on clathrin-mediated endocytosis and micropinocytosis, while caveolae-mediated endocytosis plays a major role in entrance of CT/siRNA into cerebral capillary endothelial cell bEnd.3. The nanocomplexes successfully escape from lysosomes and enter in the cytoplasm of the neuron cells, inducing effective gene silence (about 50% decrease in BACE1 mRNA levels) and reversing Aβ25–35 oligomer-induced synaptic injury. After caudal vein injection in mice, CT/siRNA display higher brain accumulation than unmodified nanocomplexes (brain drug targeting index = 2.62), and colocalize with neurons or locate nearby. In APP/PS1 transgenic mice, the nanocomplexes significantly decrease BACE1 mRNA and the amyloid plaques, suppress phosphorylated tau protein levels, as well as promote hippocampal neurogenesis. Noticeably, administration of the nanocomplexes restores the cognitive performance of the AD transgenic mice to the level of wild-type control without significant adverse effects on myelination. Our results demonstrate the CT/siRNA nanocomplexes capable of specifically directing BACE1 siRNA to brain neurons with great potential for AD therapy.

Engineering Brain-Derived Neurotrophic Factor Mrna Delivery for the Treatment of Alzheimer’s Disease

1H-MRS Assessment of the Therapeutic Effect of Bilateral Intraventricular BDNF Infusion into APP/PS1 Double Transgenic Mice

Highly Branched Poly(β-Amino Ester) Delivery of Minicircle DNA for Transfection of Neurodegenerative Disease Related Cells

Membrane Budding Inspired Biomimetic Nanocarrier Delivers Brain‐derived Neurotrophic Factor to Improve AD Cognition

1H-MRS can monitor metabolites changes of lateral intraventricular BDNF infusion into a mouse model of Alzheimer's disease in vivo.

EVs-mediated Delivery of CB2 Receptor Agonist for Alzheimer's Disease Therapy.

Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes.

Retracted: 1H-MRS Can Monitor Metabolites Changes of Lateral Intraventricular BDNF Infusion into a Mouse Model of Alzheimer’s Disease in Vivo [neuroscience 245 (2013) 40–49]

Effect of Brain-Derived Neurotrophic Factor on Tyrosine Kinase B and Endogenous Brain-Derived Neurotrophic Factor Expressions by Lateral Ventricle Infusion into AD Mice

Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice.

Retracted: 1h-Mrs Can Monitor Metabolites Changes Of Lateral Intraventricular Bdnf Infusion Into A Mouse Model Of Alzheimer'S Disease In Vivo(Retracted Article. See Vol. 254, Pg. 477, 2013)

Small Interfering RNA Delivery to the Neurons Near the Amyloid Plaques for Improved Treatment of Alzheimer׳s Disease

Raav-Mediated Delivery Of Brain-Derived Neurotrophic Factor Promotes Neurite Outgrowth And Protects Neurodegeneration In Focal Ischemic Model

Targeting Β-Secretase with RNAi in Neural Stem Cells for Alzheimer's Disease Therapy.

A Nanoformulation‐Mediated Multifunctional Stem Cell Therapy with Improved Beta‐Amyloid Clearance and Neural Regeneration for Alzheimer's Disease

Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease

Recombinant AAV-mediated Expression of Human BDNF Protects Neurons Against Cell Apoptosis in Aβ-induced Neuronal Damage Model

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration

Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of β-amyloid and ibotenic acid into the bilateral hippocampus.

Enhanced Nose-to-Brain Delivery of Combined Small Interfering RNAs Using Lesion-Recognizing Nanoparticles for the Synergistic Therapy of Alzheimer's Disease

Brain-Derived Neurotrophic Factor in Alzheimer’s Disease: Risk, Mechanisms, and Therapy